Market Brief archive

Issue 17

W/C 16 November 2026

This edition examines what happens when complexity becomes an investable asset. Nvidia's leadership crisis has exposed the value of succession planning in the world's most closely watched chipmaker. In Britain, tax changes are increasing the value of good advice just as private capital pays £1.17 billion for Canaccord Wealth. The FCA is considering wider workplace pension access to private markets, while Blackstone is funding late-stage drug development in exchange for milestone and royalty-linked returns.

16 November 2026 7 min read

The Cost of Complexity

Complexity is often presented as a problem to remove. This week, it is also the source of value.

Nvidia must prove that a business built around an unusually influential founder can preserve confidence without him. UK households and business owners are working through a tax system in which the return that matters is increasingly the return left after tax. Pension providers are being asked to decide whether higher and more complicated private-market fees can produce better outcomes. Pharmaceutical companies are using outside capital to share the cost of clinical development without giving up control of the science.

These are different stories, but they reward the same capability: understanding where risk sits, who is paid to carry it and which parts of a complicated structure genuinely improve the outcome. Complexity can support durable margins when it is difficult to replicate and useful to the customer. It destroys value when it hides weak governance, unnecessary fees or risk that nobody has priced properly.

01

Nvidia discovers the price of founder dependence

Nvidia's board accepted Jensen Huang's immediate resignation as president, chief executive and director after 33 years at the company he co-founded. Chief financial officer Colette Kress became interim chief executive while retaining the finance role, and Harvey Jones became independent chair.

The company has since created a National Security and Export Control Oversight Committee that will meet at least quarterly and use independent expertise. Its third-quarter results are due after the US market closes on 17 November, making the first earnings call without Huang an immediate test of operational confidence.

Why it matters

Nvidia is not simply another large listed company. It is central to the AI infrastructure buildout and carries meaningful weight in global equity indices. A leadership problem can therefore travel through passive funds, technology portfolios, suppliers and customers before the operating numbers change.

The next questions are practical. Can Nvidia separate product execution from the personality that represented it? Does the board have credible succession depth? Can a new compliance structure satisfy governments without slowing commercial decisions? Investors should distinguish the emotional reaction to a founder's departure from evidence about demand, margins, supply and capital commitments.

The Jura view

Founder leadership can be a competitive advantage, but only while the institution around the founder is strong enough to outlast them. Nvidia's valuation has long reflected both exceptional execution and confidence in Huang. The business now has to show how much of that advantage belongs to its systems, people and customer relationships rather than one individual. The earnings release matters, but the more durable signal will be whether governance improves without decision-making becoming slower.

Chart

Thirty-three years of founder leadership, one week of repricing

Founder tenure beside Nvidia's daily closes, 9 to 16 November.

Founder tenure

33 years

19932026

Daily close, US$

155165175178.679 Nov168.8910 Nov173.7311 Nov166.1912 Nov162.8513 Nov156.1416 Nov

Unadjusted daily closes; final value is 16 November. The move reflects several factors, not one event. Third-quarter results follow on 17 November after the US close.

Nvidia investor relations; StockAnalysis daily price history.

02

The UK Budget changes the return investors keep

From 6 April 2027, the basic, higher and additional rates on savings income will become 24, 44 and 49 per cent. The same rates will apply to property income in England, Wales and Northern Ireland. The annual cash ISA limit remains £20,000.

For business owners, the Business Asset Disposal Relief lifetime limit will fall from £1 million to £500,000. A new Founders' Relief will offer a 10 per cent rate on up to £10 million of qualifying lifetime gains, although the detailed eligibility rules remain subject to consultation.

Why it matters

A gross yield is becoming a less useful comparison on its own. Two assets offering the same headline return can produce very different results once tax, liquidity and ownership structure are considered. The Budget also creates a sharper divide between founders who meet the new relief conditions and owners relying on the broader disposal relief.

Higher savings and property rates increase the value of tax-efficient wrappers, but that does not make every product inside a wrapper suitable. Business owners considering a sale need to understand which relief, if any, is available before a transaction timetable hardens. The relevant question is not simply how to reduce tax. It is whether a different structure changes liquidity, risk or control in a way that weakens the investment case.

The Jura view

Tax is becoming part of asset selection rather than an exercise completed afterwards. That should support demand for advice, but it also raises the cost of generic recommendations. The most useful advisers will be those who can connect tax, liquidity, ownership and investment risk without allowing the tax tail to wag the investment dog.

Chart

The widening gap between gross and retained income

What £10,000 of taxable savings or property income keeps, by band.

2026 to 2027From April 2027

Basic rate · 20% to 24%

£8,000
£7,600

Higher rate · 40% to 44%

£6,000
£5,600

Additional rate · 45% to 49%

£5,500
£5,100

Retained from £10,000 of taxable savings or property income. Simplified illustration before allowances and deductions; property rates apply in England, Wales and Northern Ireland. Not personal tax advice.

HMRC, savings and property income rates.

03

Private capital pays for advice at scale

Mubadala and Centerbridge Partners agreed to acquire Canaccord Genuity's UK and Crown Dependencies wealth business in an all-cash transaction valuing it at approximately £1.17 billion. The business reported £43.4 billion of assets under management and administration at 30 June 2026.

Why it matters

The purchase is a direct bet on the economics of advice. Tax changes, pension choice and intergenerational wealth transfer are making financial decisions harder at the same time that technology can lower administration costs. A scaled platform can therefore grow revenue from advice while spreading compliance and technology spending across a larger client base.

Assets under management are not revenue and should not be compared with the purchase price as if they were. The useful questions sit underneath the headline: client retention, adviser productivity, recurring fee margins, acquisition costs and the amount of new investment needed in systems and compliance. The deal also highlights why adviser relationships can be valuable but difficult to transfer.

The Jura view

Private capital is not paying £1.17 billion merely to own portfolios. It is buying distribution, relationships and the ability to help clients make decisions that are becoming more complicated. Those qualities can support durable revenue, but only if consolidation improves the service rather than making it more distant. Trust is the asset. Scale is useful when it protects and extends that trust.

Chart

What the Canaccord transaction is buying

Client assets administered versus the value of the operating business.

£43.4bnclient assets (AUM/A)~£1.17bnenterprise value

Different measures, shown at proportional area. Client assets at 30 June 2026 belong to clients, not the buyer. No valuation multiple is implied.

Mubadala transaction announcement.

04

Workplace pensions move closer to private markets

The Financial Conduct Authority is consulting on exempting certain performance fees from the workplace pension charge cap. The 0.75 per cent cap would continue to cover base management fees, while the proposed exemption would be subject to controls around value, valuation and conflicts. Responses close on 14 January 2027, with final rules expected in summer 2027.

The FCA's modelling compares a baseline with a portfolio moving towards the Mansion House allocation. In its central simulation, median net portfolio value in 2036 rises from £520.1 billion to £530.9 billion, a 2.1 per cent increase. Median fee revenue across the modelled decade rises from £16.1 billion to £22.8 billion.

Why it matters

Private equity, venture capital and private credit often charge fees that do not fit neatly inside the current cap. Removing that barrier could widen access to long-term assets. It could also move more fee and valuation complexity into default pension products used by people who did not actively choose the allocation.

The headline return is only one part of the decision. Liquidity, fee design, valuation independence and the timing of cash flows matter. The FCA describes its modelling as illustrative rather than a forecast, and its assumptions include full liquidity and do not fully capture valuation lag and smoothing in private assets.

The Jura view

The case for private markets should not depend on calling them private. It should depend on whether the underlying assets add return, diversification or access that public markets cannot deliver as efficiently. A carefully designed exemption could improve outcomes. A loose one would simply move more of the pension pot into higher fees. Governance is not a side issue here. It is the product.

Chart

The modelled benefit and the fee bill

FCA central simulation, baseline versus Mansion House intervention.

Median net portfolio value, 2036

£520.1bn
Baseline
£530.9bn
Intervention

+£10.8bn · +2.1%

Median manager fees over ten years

£16.1bn
Baseline
£22.8bn
Intervention

+£6.7bn · about +42%

Scales differ. The two measures should not be netted against each other. FCA modelling is illustrative, not a forecast.

FCA CP26/40 technical annex.

05

Private capital moves deeper into drug development

Blackstone agreed to provide up to $1.5 billion to Pfizer through 2028 for the clinical programme behind berobenatide, a potential monthly GLP-1 obesity treatment. Pfizer keeps operational control, while Blackstone may receive regulatory and commercial milestone payments.

Five days later, Blackstone announced $750 million of Phase 3 funding for Johnson and Johnson's OLN324 eye-disease programme in exchange for certain milestone payments and single-digit royalties.

Why it matters

Drug development requires large sums before there is any certainty of approval or sales. These agreements allow pharmaceutical companies to share part of that funding burden while retaining control of development. For private capital, the return can be linked to specific clinical and commercial outcomes rather than the wider company's share price.

The structure can create attractive and less conventional cash flows, but the risk is concentrated. A failed trial, a regulatory delay or weak commercial adoption can damage the economics quickly. Investors also need to understand whether returns come from milestones, royalties, repayment priority or a mixture of all three.

The Jura view

This is private capital doing more than lending against an existing business. It is underwriting a defined development risk and being paid if the programme succeeds. The opportunity exists because the science, contracts and regulatory path are difficult to assess. That complexity can support returns, but only where the investor has genuine specialist capability. Scale alone is not an edge in a binary clinical outcome.

Chart

Two programmes, two return structures

Blackstone Life Sciences funding agreements announced this month.

Up to $2.25bn

combined funding

Pfizer · berobenatide (obesity)Up to $1.5bn · through 2028

Return: Regulatory and commercial milestones

Johnson & Johnson · OLN324 (eye disease)$750m · multi-year Phase 3

Return: Regulatory and sales milestones plus single-digit royalties

Committed funding is not guaranteed to be drawn or repaid. Both programmes carry clinical, regulatory and commercial risk.

Blackstone; Pfizer announcements.

This week in numbers

33 years

Jensen Huang's tenure at Nvidia before his immediate resignation

24% / 44% / 49%

UK savings and property income tax rates from April 2027

£1.17bn

Enterprise value of the Canaccord Wealth transaction

0.75%

Charge cap at the centre of the FCA workplace pensions consultation

$2.25bn

Blackstone life sciences funding announced with Pfizer and Johnson & Johnson

Looking ahead

  1. 17 November | Nvidia results

    Third-quarter results after the US close, the first earnings call without Jensen Huang.

  2. 14 January 2027 | FCA consultation closes

    Final day for responses on exempting performance fees from the workplace pension charge cap.

  3. 6 April 2027 | New UK tax rates

    Savings and property income rates rise to 24%, 44% and 49%.

  4. Summer 2027 | FCA final rules

    Expected publication of final rules on the charge cap exemption.

This week's stories are not an argument that complexity is always valuable. They are a reminder that the ability to manage it can be. Nvidia needs governance that survives a founder. Wealth platforms need advice that justifies their cost. Pension providers need to prove that additional fees buy something worthwhile. Life-sciences investors need specialist judgement rather than capital alone.

For long-term investors, the useful question is therefore not whether a structure looks complicated. It is whether the complexity creates a real advantage, assigns risk clearly and leaves enough value for the end investor after every layer has been paid.

This publication is for information only and does not constitute investment, legal or tax advice. Tax treatment depends on individual circumstances and may change.

We'll continue tracking the stories shaping markets, monitoring where institutional capital is moving and highlighting the trends that matter most to long-term investors.

To receive the Jura Market Brief each week, or to speak with our team, visit jura-capital.com.